Medtronic PLC  

(Public, NYSE:MDT)   Watch this stock  
Find more results for MDT
78.42
+1.04 (1.34%)
Mar 30 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 77.70 - 78.45
52 week 55.85 - 79.50
Open 77.70
Vol / Avg. 0.00/6.35M
Mkt cap 110.72B
P/E 25.10
Div/yield 0.31/1.56
EPS 3.12
Shares 1.43B
Beta 1.09
Inst. own 66%
Jun 2, 2015
Q4 2015 Medtronic Inc Earnings Release - 9:30AM EDT - Add to calendar
Mar 11, 2015
Medtronic Inc at Barclays Healthcare Conference - Webcast
Mar 3, 2015
Medtronic Inc at Cowen Health Care Conference
Feb 17, 2015
Q3 2015 Medtronic Inc Earnings Release
Feb 17, 2015
Q3 2015 Medtronic Inc Earnings Call - Webcast
Jan 12, 2015
Medtronic Inc at JPMorgan Healthcare Conference
Jan 6, 2015
Medtronic Inc Extraordinary Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin 22.63% 18.02%
Operating margin 33.07% 22.42%
EBITD margin - 33.33%
Return on average assets 8.34% 8.42%
Return on average equity 19.79% 16.08%
Employees 49,000 -
CDP Score - 81 D

Address

20 On Hatch Lower Hatch Street, Dublin 2
DUBLIN, 2
Ireland
+353-1-4381700 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medtronic plc is a medical technology, services and solutions company. The Company offers its products to hospitals, physicians, clinicians and patients in over 160 countries. The Company�s portfolio includes surgical, respiratory and monitoring, and vascular therapies solutions along with a line of patient care products to alleviate pain, restore health and extend life for people. The Company operates in three segments: Cardiac and Vascular Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment manufactures and markets device-based medical therapies for Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart and Endovascular. The Restorative Therapies Group segment manufactures and markets device-based medical therapies for Spine, Neuromodulation and Surgical Technologies. The Diabetes Group segment manufactures and markets device-based medical therapies for diabetes. Medtronic Inc is a wholly owned subsidiary of Medtronic plc.

Officers and directors

Omar Ishrak Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Gary L. Ellis Chief Financial Officer, Senior Vice President, Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Carol A. Surface Chief Human Resource Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Michael J. Coyle Executive Vice President, Group President - Cardiac and Vascular Group
Age: 51
Bio & Compensation  - Reuters
Hooman C. Hakami Executive Vice President and Group President of the Medtronic Diabetes Group
Age: 44
Bio & Compensation  - Reuters
Robert ten Hoedt Executive Vice President and President, EMEAC
Age: 53
Bio & Compensation  - Reuters
Christopher J. O'Connell Executive Vice President and Group President - Restorative Therapies Group
Age: 47
Bio & Compensation  - Reuters
Richard E. Kuntz M.D. Senior Vice President, Chief Scientific, Clinical and Regulatory Officer
Age: 57
Bio & Compensation  - Reuters
Bradley E. Lerman Senior Vice President, General Counsel, Corporate secretary, Director
Age: 57
Bio & Compensation  - Reuters
Geoffrey S. Martha Senior Vice President - Strategy and Business Development
Age: 44
Bio & Compensation  - Reuters